共 41 条
- [22] Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated VasculitisClinical Drug Investigation, 2023, 43 : 595 - 603Ivan D. NguyenEvan S. SinnathambyJoseph MasonBretton UrbanElisa E. NeuchatDanielle M. WengerShahab AhmadzadehSahar ShekoohiAlan D. Kaye
- [23] Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated VasculitisCLINICAL DRUG INVESTIGATION, 2023, 43 (08) : 595 - 603Nguyen, Ivan D.Sinnathamby, Evan S.Mason, JosephUrban, BrettonNeuchat, Elisa E.Wenger, Danielle M.Ahmadzadeh, ShahabShekoohi, SaharKaye, Alan D.
- [24] Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitisMODERN RHEUMATOLOGY, 2022, 32 (03) : 475 - 483Harigai, MasayoshiTakada, Hideto
- [25] Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical StudyPLOS ONE, 2016, 11 (10):Bekker, PirowDairaghi, DanielSeitz, LisaLeleti, ManmohanWang, YuErtl, LindaBaumgart, TrageenShugarts, SarahLohr, LisaDang, TonMiao, ShichangZeng, YibinFan, PingchenZhang, PenglieJohnson, DanielPowers, JayJaen, JuanCharo, IsraelSchall, Thomas J.
- [26] Safety and Efficacy of Oral Chemokine Receptor 1 Antagonist CCX354-C in a Phase 2 Rheumatoid Arthritis StudyARTHRITIS AND RHEUMATISM, 2011, 63 (12): : 4046 - 4046Tak, Paul P.Balanescu, AndraTseluyko, ViraBojin, SilviaDrescher, EditDairaghi, DanMiao, ShichangMarchesin, VittorioJaen, JuanBekker, PirowSchall, Thomas J.
- [27] Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated VasculitisACR OPEN RHEUMATOLOGY, 2020, 2 (11) : 662 - 671Merkel, Peter A.Niles, JohnJimenez, RichardSpiera, Robert F.Rovin, Brad H.Bomback, AndrewPagnoux, ChristianPotarca, AntoniaSchall, Thomas J.Bekker, Pirow
- [28] A Randomized, Double-Blind, Phase II Study of Glucocorticoid Replacement by Vilobelimab, an Anti-C5a Monoclonal Antibody, in ANCA-Associated VasculitisARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1054 - 1055Merkel, PeterHellmich, BernhardPfaff, AnjaMuller, CarinaStartseva, ElenaJayne, David
- [29] Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated VasculitisARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1363 - 1364Geetha, DuvuruCortazar, FrankBruchfeld, AnnetteKarras, AlexandreMerkel, PeterJayne, David
- [30] Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study (vol 11, e0164646, 2016)PLOS ONE, 2019, 14 (01):Bekker, PirowDairaghi, DanielSeitz, LisaLeleti, ManmohanWang, YuErtl, LindaBaumgart, TrageenShugarts, SarahLohr, LisaDang, TonMiao, ShichangZeng, YibinFan, PingchenZhang, PenglieJohnson, DanielPowers, JayJaen, JuanCharo, IsraelSchall, Thomas J.